Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | SMO | Q99835 | 6/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 4/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597003 | 1.00 | GPR119 (0.36) | GPR119SMOFPR2BTKDDB1 | |
| SCHEMBL15023134 | 0.92 | BTK (0.35) | GPR119SMOFPR2BTKDDB1 | |
| SCHEMBL12186202 | 0.92 | BTK (0.35) | GPR119SMOFPR2BTKDDB1 | |
| SCHEMBL12186200 | 0.91 | BTK (0.37) | GPR119SMOFPR2BTKDDB1 | |
| SCHEMBL15022853 | 0.91 | BTK (0.37) | GPR119SMOFPR2BTKDDB1 | |
| SCHEMBL15022725 | 0.86 | BTK (0.36) | GPR119SMOBTK | |
| SCHEMBL12185916 | 0.86 | BTK (0.36) | GPR119SMOBTK | |
| SCHEMBL790466 | 0.85 | BTK (0.37) | GPR119SMOFPR2BTK | |
| SCHEMBL790465 | 0.85 | BTK (0.37) | GPR119SMOFPR2BTK | |
| SCHEMBL15023166 | 0.84 | SMO (0.33) | GPR119SMOBTKPANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| EP-2571864-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146335-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | GPR119 1/4885SMO 1484/4885FPR2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.